Status:
COMPLETED
Testing the Effects of Methylphenidate on Multiple Sclerosis
Lead Sponsor:
Kessler Foundation
Conditions:
Fatigue in Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in da...
Detailed Description
As highlighted by the National Clinical Advisory Board of the National Multiple Sclerosis Society (NMSS), "fatigue is the most common MS (multiple sclerosis) symptom", affecting up to 95% of individua...
Eligibility Criteria
Inclusion
- Diagnosis of Multiple Sclerosis
- Age: 18-65 years old
Exclusion
- Participants must be free of: corticosteroids, cannot be currently taking modafinil, amantadine or other psychostimulants.
- Participants must be MS relapse free at least during the previous 4 weeks.
- Participants cannot consume more than ≧300mg of caffeine per day.
- Thyroid disease
- Anemia
- Decreased vitamin D.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 4 2025
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT02286557
Start Date
October 1 2014
End Date
March 4 2025
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kessler Foundation
East Hanover, New Jersey, United States, 07936